THE Therapeutic Goods
Administration is investigating
a “significant safety concern”
involving idelalisib 100mg and
150mg tablets which are marketed
in Australia as Zydelig.
Product sponsor Gilead Sciences
has advised the TGA of a potential
increased risk of serious adverse
events including death, mostly due
to infections, in patients receiving
the medicine for the treatment of
chronic lymphocytic leukaemia and
relapsed indolent non-Hodgkin’s
lymphoma, in phase 3 clinical trials.
The TGA is reviewing information
already received and is seeking
further information from Gilead.
In the meantime the company is
advising prescribers to avoid using
idelalisib as a first line treatment.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Mar 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Mar 16
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.